Dr. Reddy's Laboratories Ltd
Dr. Reddy’s Laboratories is an India-based pharmaceutical group headquartered in Hyderabad, with operations spanning research, manufacturing, and commercialization across multiple countries. Its business covers active pharmaceutical ingredients, generics, branded generics, biosimilars, over-the-counter products, and pharmaceutical services through a network of subsidiaries and affiliates.
Business
Share of revenueFinished-dosage medicines, branded generics, biosimilars, and related generic products.
APIs, intermediates, semi-finished formulations, and customer-specific pharma services.
Discovery-stage biotechnology and proprietary product activities.
Customers
Customers include hospitals, pharmacies, wholesalers, distributors, and healthcare providers that source generic and branded medicines for patient use. The company also sells APIs and contract pharma services to pharmaceutical and biotechnology customers that need manufacturing or development support, including customized drug-discovery collaborations and customer-specific ingredient supply.
They buy finished generic and branded medicines for downstream retail and patient distribution.
They source prescription medicines and therapeutic products for clinical use.
They purchase APIs, intermediates, and contract services for drug development and supply.
They buy OTC health products for self-care and non-prescription use.
They engage in discovery and proprietary product collaborations, especially in oncology and inflammation.
Strategy
The company’s strategy centers on expanding its generics and branded-generic franchise while maintaining breadth across APIs, services, and specialty pipelines. Its portfolio also includes biosimilars, OTC products, and discovery-stage assets, which diversify the business beyond traditional generics and support longer-term pipeline optionality.
This remains the core scale business and supports commercial reach across multiple markets.
API and customer-specific services deepen supply relationships and diversify revenue streams.
Biosimilars and proprietary programs can create differentiated products beyond commoditized generics.
Geography
The company is headquartered in Hyderabad, India, with principal research facilities in Telangana, Andhra Pradesh, and Cambridge in the United Kingdom. Its principal manufacturing base is spread across India, Mexico, and the UK, while key markets include India, Russia, the United States, and Germany.
Risks
The business is exposed to generic-drug competition, pricing pressure, and regulatory scrutiny in multiple jurisdictions. It also carries product-development and impairment risk from its proprietary and discovery-stage assets, alongside manufacturing, supply-chain, and foreign-exchange exposure from its multi-country footprint.
- Generic pricing pressureImpact: HighLikelihood: High
A large share of revenue comes from generics, which face intense competition and price erosion.
Exposure: Global Generics
- Regulatory and quality complianceImpact: HighLikelihood: High
Pharmaceutical manufacturing and sales require approvals and ongoing inspection in multiple jurisdictions.
Exposure: Manufacturing and marketed products
- Pipeline and impairment riskImpact: HighLikelihood: Medium
Discovery-stage and differentiated products can fail technically or be impaired if prospects weaken.
Exposure: Aurigene Oncology and proprietary products
- Foreign-exchange volatilityImpact: MediumLikelihood: High
Revenue and costs span multiple currencies and geographies, creating translation and transaction exposure.
Exposure: International operations
- Supply-chain and manufacturing disruptionImpact: MediumLikelihood: Medium
Production is spread across India, Mexico, and the UK, increasing coordination and continuity risk.
Exposure: Multi-site manufacturing network
Accounting
Judgemental itemsGoodwill is not amortized and must be tested for impairment, which can create large non-cash charges.
Impact: Reported earnings and equity
Development and acquired intangibles may need write-downs if expected benefits weaken.
Impact: Operating results and asset values
Derivative instruments are carried at fair value, creating mark-to-market volatility.
Impact: Financial income/expense and equity
Equity-settled and cash-settled awards are measured at fair value.
Impact: Compensation expense and equity
Committed spending on plant and equipment affects future cash outflows and capacity expansion.
Impact: Liquidity and investment profile
Similar listed companies
Publicly listed companies with a comparable business focus.
Arrowhead Pharmaceuticals, Inc
ARWR · Pharmaceutical Preparations
Arrowhead Pharmaceuticals is a U.S.-based biopharmaceutical company focused on developing RNA interference medicines that silence disease-causing genes.
Silence Therapeutics plc
SLNCF · Pharmaceutical Preparations
Silence Therapeutics plc is a biotechnology company focused on discovering and developing siRNA-based medicines that silence disease-associated genes through RNA interference.
Orion Oyj
ORNBV · Drug Manufacturers - General
Orion is a Finnish pharmaceutical company that operates globally, focusing on the development, manufacturing, and marketing of human and animal medicines, as…
Teva Pharmaceutical Industries Limited
TEVA · Pharmaceutical Preparations
Longduoduo Co Ltd
LDDD · Services-Health Services
Longduoduo Co Ltd is a U.S.-listed company with operating subsidiaries in Inner Mongolia and Beijing that generates revenue from two main activities: direct…
Ridgetech Inc.
RDGT · Retail-Drug Stores and Proprietary Stores
Last updated: 28/09/2026